• 1. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 4. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

Latest Research Advances on 9H-Pyrrolo[2,3-b:4,5-c']dipyridine (CAS: 26422-85-5) in Chemical Biology and Pharmaceutical Applications

The compound 9H-Pyrrolo[2,3-b:4,5-c']dipyridine (CAS: 26422-85-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This heterocyclic scaffold, characterized by its fused pyrrolopyridine rings, exhibits remarkable versatility in drug discovery, particularly in the development of kinase inhibitors and anticancer agents. Recent studies have explored its role as a privileged structure in medicinal chemistry, enabling the design of novel bioactive molecules with enhanced selectivity and potency.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 9H-Pyrrolo[2,3-b:4,5-c']dipyridine derivatives as selective inhibitors of cyclin-dependent kinases (CDKs), with compound 7a showing IC50 values below 10 nM against CDK2 and CDK9. The research team employed structure-activity relationship (SAR) analysis to optimize the substitution pattern at the 2- and 7-positions of the core scaffold, significantly improving both potency and pharmacokinetic properties. Molecular docking studies revealed that these derivatives bind to the ATP-binding pocket of CDKs through key hydrogen bond interactions with the hinge region.

In oncology research, novel 9H-Pyrrolo[2,3-b:4,5-c']dipyridine-based compounds have shown promising results against resistant cancer cell lines. A Nature Communications paper (2024) reported the development of a dual inhibitor targeting both EGFR and MET tyrosine kinases, with the lead compound (designated PD-26422) demonstrating potent activity against T790M/L858R mutant EGFR (IC50 = 2.3 nM) while maintaining good selectivity over wild-type EGFR. The compound exhibited significant tumor growth inhibition in xenograft models of non-small cell lung cancer, with a tumor growth inhibition rate of 78% at 50 mg/kg dose.

The synthetic accessibility of 9H-Pyrrolo[2,3-b:4,5-c']dipyridine derivatives has also been improved through recent methodological advances. A 2024 Organic Letters publication described a novel palladium-catalyzed cascade cyclization approach that allows for the efficient construction of the core structure in three steps from commercially available starting materials, with yields exceeding 65%. This synthetic route has enabled rapid diversification of the scaffold for structure-activity relationship studies.

Beyond oncology applications, researchers have explored the potential of 9H-Pyrrolo[2,3-b:4,5-c']dipyridine derivatives in neurodegenerative diseases. A recent study in ACS Chemical Neuroscience identified several compounds with potent activity against GSK-3β (glycogen synthase kinase-3 beta), a key target in Alzheimer's disease pathology. The most promising candidate showed good blood-brain barrier permeability in in vitro models and reduced tau hyperphosphorylation in cellular assays.

From a drug development perspective, several 9H-Pyrrolo[2,3-b:4,5-c']dipyridine-based candidates have entered preclinical evaluation. A particularly noteworthy example is PRD-26422, currently under investigation as a potential treatment for inflammatory diseases, showing potent JAK1/3 inhibitory activity with favorable selectivity over JAK2. The compound demonstrated excellent efficacy in a murine model of rheumatoid arthritis, reducing joint inflammation by 85% at a 10 mg/kg dose.

Recent computational studies have provided deeper insights into the molecular recognition patterns of 9H-Pyrrolo[2,3-b:4,5-c']dipyridine derivatives. Molecular dynamics simulations published in the Journal of Chemical Information and Modeling (2024) revealed that the planar aromatic system of the core scaffold facilitates π-stacking interactions with aromatic residues in protein binding sites, while the nitrogen atoms participate in crucial hydrogen bonding networks. These findings are guiding the rational design of next-generation derivatives with improved target engagement.

As research progresses, the 9H-Pyrrolo[2,3-b:4,5-c']dipyridine scaffold continues to demonstrate its value as a versatile platform for drug discovery. The compound's ability to serve as a bioisostere for various heterocyclic systems, combined with its favorable physicochemical properties, positions it as an important tool in addressing challenging therapeutic targets. Future research directions include exploring its application in PROTAC design and covalent inhibitor development, as well as further optimization of its ADME properties for clinical translation.

• 244-76-8(a-Carboline)
• 243-38-9(6H-Quinindoline)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)